Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519303 | 0.89 | SMN1; SMN2 (0.49) | ACACBSMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL5516274 | 0.89 | SMN1; SMN2 (0.49) | ACACBSMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL5519107 | 0.89 | ACACB (0.46) | ACACBSMN1; SMN2HPGDL3MBTL1LMNA | |
| SCHEMBL5520765 | 0.89 | HSD17B10 (0.44) | ACACBSMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL5521109 | 0.85 | ACACB (0.41) | ACACBSMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL5518049 | 0.83 | ACACB (0.42) | ACACBSMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL5532649 | 0.83 | ACACB (0.41) | ACACBSMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL5522141 | 0.83 | ACACB (0.41) | ACACBSMN1; SMN2HPGD | |
| SCHEMBL14451330 | 0.80 | HSD17B10 (0.43) | ACACBSMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL14451329 | 0.80 | HSD17B10 (0.43) | ACACBSMN1; SMN2HPGDL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | ACACB 1086/4885SMN1; SMN2 897/4885HPGD 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.